Meredith Buxton

6.5k total citations
13 papers, 177 citations indexed

About

Meredith Buxton is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Meredith Buxton has authored 13 papers receiving a total of 177 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Meredith Buxton's work include Advanced Breast Cancer Therapies (3 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Meredith Buxton is often cited by papers focused on Advanced Breast Cancer Therapies (3 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Meredith Buxton collaborates with scholars based in United States, Switzerland and Canada. Meredith Buxton's co-authors include Richard S. Garfein, Peter R. Kerndt, Edward V. Morse, Steffanie A. Strathdee, Lawrence J. Ouellet, Laura J. Esserman, David Vlahov, Don C. Des Jarlais, Donald A. Berry and Laura van ‘t Veer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

Meredith Buxton

11 papers receiving 174 citations

Peers

Countries citing papers authored by Meredith Buxton

Since Specialization

Citations

This map shows the geographic impact of Meredith Buxton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meredith Buxton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meredith Buxton more than expected).

Fields of papers citing papers by Meredith Buxton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meredith Buxton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meredith Buxton. The network helps show where Meredith Buxton may publish in the future.

Co-authorship network of co-authors of Meredith Buxton

This figure shows the co-authorship network connecting the top 25 collaborators of Meredith Buxton. A scholar is included among the top collaborators of Meredith Buxton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meredith Buxton. Meredith Buxton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. 2024 ·Journal of Clinical Oncology ·John Frederick De Groot, Timothy F. Cloughesy, Donald A. Berry, Meredith Buxton, Howard Colman, Benjamin M. Ellingson, Gary Gordon, Andrew B. Lassman, Michael Lim, Ingo K. Mellinghoff, Erik P. Sulman, Michael Weller, Patrick Y. Wen, (unknown), Tom Mikkelsen, Scott Owen, Warren Mason, Jan Drappatz, (unknown), James Perry, (unknown)	0
2	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. 2021 ·Journal of Clinical Oncology ·Patrick Y. Wen, Ingo K. Mellinghoff, Meredith Buxton, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, Gary Gordon, Mustafa Khasraw, Andrew B. Lassman, Michael Lim, James Perry, Kirk Tanner, Michael Weller, W.K. Alfred Yung, Timothy F. Cloughesy, (unknown)	5
3	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. 2020 ·Journal of Clinical Oncology ·Meredith Buxton, Brian M. Alexander, Donald A. Berry, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, Gary Gordon, Mustafa Khasraw, Andrew B. Lassman, Wenbin Li, Michael Lim, Ingo K. Mellinghoff, James Perry, Erik P. Sulman, Kirk Tanner, Michael Weller, Patrick Y. Wen, W.K. Alfred Yung, Timothy F. Cloughesy, (unknown)	7
4	Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL 2016 ·Cancer Research ·Denise M. Wolf, Christina Yau, Ashish Sanil, Lamorna Brown Swigart, Gillian L. Hirst, Meredith Buxton, Melissa Paoloni, (unknown), Olufunmilayo Olopade, Hope S. Rugo, (unknown), Fraser Symmans, Don Berry, Laura J. Esserman, Laura van ‘t Veer	2
5	Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL 2016 ·Cancer Research ·(unknown), Brian Leyland‐Jones, (unknown), Marco Paoloni, Laura van ‘t Veer, Angela DeMichele, Meredith Buxton, Nola M. Hylton, Douglas Yee, Julia L. Clennell, Christina Yau, Ashish Sanil, (unknown), Deborah L. Berry, L. Esserman	0
6	Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer 2016 ·Cancer Research ·Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Meredith Buxton, Melissa Paoloni, (unknown), Olufunmilayo Olopade, (unknown), Fraser Symmans, Hope S. Rugo, (unknown), Laura J. Esserman, Laura van ‘t Veer	5
7	Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. 2015 ·Journal of Clinical Oncology ·Debu Tripathy, A. Jo Chien, Nola M. Hylton, Meredith Buxton, (unknown), Anne M. Wallace, Andres Forero, Henry G. Kaplan, Rita Nanda, Kathy S. Albain, Stacy L. Moulder, Barbara Haley, Angela DeMichele, W. Fraser Symmans, Laura van ‘t Veer, Melissa Paoloni, Laura J. Esserman, Donald A. Berry, Douglas Yee	23
8	Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL 2015 ·Cancer Research ·Denise M. Wolf, Christina Yau, Ashish Sanil, Anneleen Daemen, Laura M. Heiser, Joe W. Gray, Lamorna Brown Swigart, Susan Flynn, Gillian L. Hirst, (unknown), Meredith Buxton, Angela DeMichele, Nola Hylton, Fraser Symmans, Douglas Yee, Melissa Paoloni, Laura J. Esserman, (unknown), Hope S. Rugo, Olufunmilayo I. Olopade, Laura van ‘t Veer	2
9	Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. 2014 ·Journal of Clinical Oncology ·Meredith Buxton, (unknown), Angela DeMichele, Jane Perlmutter, Nola M. Hylton, Douglas Yee, Laura van’t Veer, W. Fraser Symmans, Michael Hogarth, Julia Lyandres, Sarah E. Davis, Susan Flynn, Melissa Paoloni, Donald A. Berry, Laura J. Esserman, (unknown)	2
10	532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial 2014 ·European Journal of Cancer ·Annuska M. Glas, Janneke G. C. Peeters, (unknown), Denise M. Wolf, Ashish Sanil, (unknown), (unknown), Shai Linn, Meredith Buxton, A. DeMichele, Nola M. Hylton, (unknown), Douglas Yee, Marco Paoloni, L. Esserman, Don Berry, H. S. Rugo, (unknown), Laura van ‘t Veer	7
11	Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL 2013 ·Cancer Research ·HS Rugo, O. Olopade, Angela DeMichele, Laura van ‘t Veer, Meredith Buxton, Nola Hylton, Douglas Yee, (unknown), Anne M. Wallace, (unknown), Julia Lyandres, (unknown), Ashish Sanil, Donald A. Berry, Laura J. Esserman	48
12	Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) 2011 ·Breast Cancer Research and Treatment ·(unknown), Cheryl Lin, Meredith Buxton, Dan H. Moore, Helen Krontiras, Lisa A. Carey, (unknown), Leslie L. Montgomery, Debasish Tripathy, Constance D. Lehman, Minetta C. Liu, (unknown), Christina Yau, Donald A. Berry, Laura J. Esserman	21
13	Association between injection practices and duration of injection among recently initiated injection drug users 2004 ·Drug and Alcohol Dependence ·Meredith Buxton, David Vlahov, Steffanie A. Strathdee, Don C. Des Jarlais, Edward V. Morse, Lawrence J. Ouellet, Peter R. Kerndt, Richard S. Garfein	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact